Omnihealth Practice

HEMATOLOGY

Redefining the cure: 7-year data shows lasting survival advantage with A+AVD in advanced cHL

18 Sep 2026

IV iron use during acute infections associated with lower mortality in IDA

17 Jan 2026

Extending treatment with brentuximab vedotin to stage III classical Hodgkin lymphoma

23 Jan 2026

Ruxolitinib in high-risk PV: Addressing unmet needs and delivering durable clinical benefit

12 Sep 2025

Shaping the future of myelofibrosis care: The role of momelotinib in addressing anemia, spleen and symptom burden in once-daily oral regimen

12 Sep 2025

Navigating the CAR-T frontier in hematological malignancies in Asia

29 Aug 2025

Beyond transfusion - The emerging role of luspatercept in transfusion-dependent β-thalassemia

05 Mar 2024

A case sharing: Exploring the long-term benefits of gilteritinib in FLT3+ RR AML patients

17 Nov 2023

Transforming MCL care: The potential role of BTKi-based regimens in front-line treatment

06 Sep 2023

Beyond high-risk MM with Isa combination

10 May 2023

Promising real-world evidence of all-oral triplet combination of ixazomib, lenalidomide, and dexamethasone (IRd) for the treatment of rrMM

05 Jan 2022

Real-world analysis found ixazomib triple therapy effective in the management of relapsed/refractory multiple myeloma

28 Feb 2021

Bruton’s tyrosine kinase inhibitors delay disease progression and extend survival in patients with relapsed/refractory mantle cell lymphoma

30 Dec 2020

Denosumab as a well-tolerated and effective bone targeting treatment option for multiple myeloma patients with osteolytic lesions

31 Dec 2020

Brentuximab vedotin serves as a viable option to combine with chemotherapy for advanced stage Hodgkin lymphoma

31 Dec 2020

Recent advances in management of chronic lymphocytic leukemia patients with a novel kinase inhibitor

29 Oct 2020

Optimizing therapy in mantle cell lymphoma

28 Feb 2019

Evolution in the treatment of CD30-positive lymphomas: The role of brentuximab vedotin

30 Apr 2019

Management of multiple myeloma in Hong Kong

31 Aug 2019

Ride with the tide: Treatment strategies for B-cell non-hodgkin lymphoma

30 Oct 2019

The use of daratumumab in multiple myeloma: Developing novel immunotherapy strategies to prolong survival

31 Aug 2020

A local case report of relapsed/refractory hodgkin lymphoma: A positive outcome with brentuximab vedotin

30 Jun 2019

Advanced-stage Hodgkin lymphoma in an elderly patient: A case report highlighting the efficacy of brentuximab vedotin treatment

30 Jun 2020

Ixazomib in treatment of relapsed/refractory multiple myeloma: A case review from Hong Kong

29 Apr 2020

Extending endocrine care beyond β-thalassemia major: International consensus guideline in children and adolescents

07 Nov 2025

Simplifying care: Alleviating treatment burden in APL with oral arsenic trioxide

26 Jul 2025

Unlocking the full potential of CAR T-cell therapy in R/R MM: A consensus from the IMWG Immunotherapy Committee

22 May 2025

Pinnacle 4-year data from OPTIC supports durable efficacy of ponatinib in CP-CML with BCR::ABL1 T315I mutation

29 Dec 2024

Reshaping CLL care: Acalabrutinib-based regimens at the forefront of CLL management

09 May 2024

Blueprints for the management of Ph-negative MPNs among Asian populations: Expert consensus from the Asian Myeloid Working Group

13 Mar 2024

Local case series: Optimizing long-term management of RRMM with all-oral ixazomib regimen

21 Nov 2023

Momelotinib: Explore MOMGEMFIN as largest real world data

11 Mar 2026

Navigating the CAR-T frontier in hematological malignancies in Asia

Chimeric antigen receptor T-cell (CAR-T) therapy has become a groundbreaking treatment for hematologic malignancies, particularly in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) and acute lymphoblastic leukemia (ALL). Building on its success in these indications, CAR-T therapy is now emerging as a promising option for patients with relapsed or refractory multiple myeloma (R/R MM), offering new hope for those with limited treatment options. However, the challenge of introducing CAR-T therapy into healthcare systems in Asia, is multifaceted. In an interview with Omnihealth Practice, Dr. Sivakumar Palaniappan, a consultant hematologist from Pantai Hospital Kuala Lumpur, Malaysia shed light on the region’s diverse healthcare landscape and the need for careful consideration of demographic, economic, and cultural factors to ensure broad and equitable access to this innovative treatment.

29 Aug 2025

Dr. Sivakumar Palaniappan

Consultant Hematologist,
Pantai Hospital Kuala Lumpur,
Kuala Lumpur, Malaysia

Simplifying care: Alleviating treatment burden in APL with oral arsenic trioxide

The combination of oral arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) greatly improves survival and quality of life for acute promyelocytic leukemia (APL) patients compared to traditional chemotherapy The invention of oral A

26 Jul 2025

Dr. Singh Gill Harinder Harry

Clinical Assistant Professor,
Department of Medicine,
The University of Hong Kong

ASH 2025

December 6-9 , 2025 | Orlando, United States

An equally efficacious and safe alternative: The once-weekly carfilzomib-based therapy

HEMATOLOGY

04 Apr 2022

Dr. Keith Stewart

Professor of Medicine,
Director,
Princess MargarXet Cancer Centre
Vice President,
Cancer, University Health Network,
Toronto, Canada

Extending endocrine care beyond β-thalassemia major: International consensus guideline in children and adolescents

Thalassemia arises from mutations in the α- or β-globin genes, with 5%-10% of the global population carrying α-thalassemia mutations and at least 40,000 children born with β-thalassemia annually. The disease is most prevalent in the Mediterranean, Middle East, Indian subcontinent, China, and Southeast Asia.

07 Nov 2025

Professor Dr. Muhammad Yazid Jalaludin

Senior Consultant Pediatric Endocrinologist,
Department of Pediatrics,
Universiti Malaya Medical Centre,
Kuala Lumpur, Malaysia

A case sharing: Exploring the long-term benefits of gilteritinib in FLT3+ RR AML patients

Patients with relapsed/refractory (RR) acute myeloid leukemia (AML) have a high risk of relapse and poor overall survival (OS) without hematopoietic stem cell transplantation (HSCT).1 The key to managing these patients is to induce remission so that HSCT becomes possible.1 This is particularly true

17 Nov 2023

Dr. Singh Gill Harinder Harry

Clinical Assistant Professor,
Department of Medicine,
The University of Hong Kong

SC daratumumab approved in the EU as first treatment for high-risk SMM

Smoldering multiple myeloma (SMM) is an asymptomatic precursor of multiple myeloma, with high-risk patients facing a substantial likelihood of progression to symptomatic disease. Until now, there have been no approved treatment options for this patient population, and standard care has been limited to close monitoring. The recent European Commission (EC) approval of subcutaneous daratumumab, based on phase 3 AQUILA trial results, introduces the first licensed treatment for high-risk SMM and provides a new opportunity to delay or prevent progression to symptomatic disease.

16 Oct 2025

FDA approves brentuximab vedotin combination as ECHELON-3 demonstrates significant survival benefit in R/R DLBCL

The United States (US) Food and Drug Administration (FDA) has approved brentuximab vedotin (BV) in combination with lenalidomide and a rituximab product (Len + R) for adults with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after two or more systemic therapies, including those with diffuse LBCL (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), who are ineligible for autologous stem cell transplantation (auto-HSCT) or CAR T-cell therapy.¹

03 Jun 2025

HEMATOLOGY

The TRACTION trial: Slashing transfusions in major non-cardiac surgery with TXA

15 May 2026

Redefining the cure: 7-year data shows lasting survival advantage with A+AVD in advanced cHL

For three decades, the doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) regimen has served as the frontline standard of care for patients with advanced classical Hodgkin lymphoma (cHL).1,2 While this disease is relatively curable, a notable proportion of patients still face relapses or re

18 Sep 2026

Dr. David Chao

Resident Specialist